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Abstract The involvement of calcitonin gene-related
peptide (CGRP) in migraine pathophysiological mecha-
nisms is shown by the facts that CGRP can induce
migraine and that two CGRP antagonists, olcegepant
and telcagepant, are effective in the treatment of migraine
attacks. Increase of the neuropeptide CGRP during
migraine and cluster headache attacks in the extracerebral
circulation as measured in the external jugular vein (EJV)
has been regarded as an established fact. Then in 2005, a
study, using the migraine patients as their own controls,
showed; however, no changes of CGRP in EJV. For
migraine there is thus some uncertainty as to whether
CGRP is increased in all migraine patients and more
research is needed. In contrast, there are three ‘positive’
studies in cluster headache in which both sumatriptan, O2
and spontaneous resolution normalized CGRP. The source
of an increase of CGRP in EJV is most likely a ‘nervous
vasodilatory drive’ in the extracranial vascular bed. It
remains an enigma how the observed increase of CGRP in
the EJV fits into the mechanisms of migraine and cluster
headache.
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Introduction
The involvement of calcitonin gene-related peptide
(CGRP) in migraine pathophysiological mechanisms is
convincingly shown by the facts that CGRP can induce
migraine [1] and that two CGRP antagonists, olcegepant
[2] and telcagepant [3, 4], are effective in the treatment of
migraine attacks.
CGRP is a 37-amino-acid neuropeptide, first identi-
fied in 1982 [5]. CGRP belongs to a family of peptides
which includes calcitonin, adrenomedullin and amylin.
There is a wide distribution of CGRP immunoreactive
structures in the peripheral nervous system and in the
CNS [6, 7, 8]. CGRP-containing nerves innervate blood
vessels in various regions of the body and the neuro-
peptide is a potent vasodilator. The physiological role of
CGRP in the cardiovascular system is still not well
understood [6]. In the cerebral circulation there is a
dense supply of CGRP-containing nerve fibres which
originate in the trigeminal ganglion [8, 9, 10] and the
most pronounced action of CGRP is that of intracranial
vasodilatation [11]. In addition, CGRP is also involved
in pain sensations [12–14]. For general reviews of
CGRP, see [15, 16].
Until recently it has been an established fact that CGRP
is increased in external jugular blood when measured
during attacks of migraine [17, 18] and cluster headache
[19–21]. In 2005 a study with intra-patient control found,
however, no change when CGRP was measured in the EJV
during and outside of migraine attacks without aura [22].
This was the case with a new validated assay [23] and also
with the very same assay used previously [17–19]. It has
been stated that ‘‘CGRP is released in prolonged, severe
attacks of migraine’’ [17, 24], but the duration of attacks
was similar in these two studies [17, 22] (see below). Thus,
the discrepancy between these studies remains unresolved
until now.
In the following the available studies shall be analysed
in depth followed by a conclusion.
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Animal studies
CGRP is involved in the transient arteriolar dilatation that is
characteristic of cortical spreading depression (CSD) [25, 26].
One would therefore expect an increase of CGRP after CSD
in the blood drained from the brain. This possibility was
investigated in cats after CSD by sampling of blood for
determination of CGRP from the EJV [27]. Blood was sampled
during passage of a wave of CSD and 60 min later. No increase
of CGRP was found [27]. It has been shown in cats that the
internal carotid system is vestigial [27, 28]. Most of thecerebral
blood flow thus passes through the rete mirabile and the extra-
cranial venous circulation [28]. It is therefore unlikely that the
negative finding in this study could be attributed to the sam-
pling in the EJV [27]. CGRP does not readily cross the blood
brain barrier (BBB) [29, 30] and it was suggested that, even if
CSD cause release of CGRP locally, it did not cross the BBB
into the venous circulation in significant concentrations [27].
In contrast, trigeminal stimulation caused an increase
(22–26%) of CGRP in the EJV in cats in two studies [18, 31].
In one study there was 66% increase in substance P [31],
whereas substance P was not measured in the other study
[18]. The effect on CGRP levels could in one study be
antagonized by administration of either sumatriptan or
dihydroergotamine [18]. The effect of trigeminal stimula-
tion is an increase in cerebral blood flow in cats [18, 32] and
this increase could be reduced with sumatriptan and dihy-
droergotamine [18]. In contrast, electrical stimulation of the
trigeminal ganglion in monkeys resulted in a frequency-
dependent decrease in external carotid resistance but had no
effect on bulk flow and resistance in the internal carotid
circulation [33]. Trigeminal ganglion stimulation in rats
caused an increase of facial skin blood flow and this increase
was inhibited by a CGRP antagonist [34]. Stimulation of
trigeminal ganglion caused an increase of CGRP in jugular
vein and this increase could be blocked by sumatriptan [35].
Stimulation of superior sagittal sinus in cats caused an 85%
rise in CGRP in the EJV and a 300% rise in VIP, but no
increase in substance P [36]. The increase of CGRP levels
could be inhibited by avitriptan [37].
The animal studies thus indicate that CGRP is increased
in the EJV if there is a ‘nervous vasodilatory drive’. Due to
the vestigial cephalic circulation of animals (see above), it
is not possible to establish whether the observed increase of
CGRP in EJV is the result of an intracranial or extracranial
release of CGRP.
In one rat study, nitroglycerin (NTG) in doses of 2 and
50 lg/kg per min failed to change CGRP levels in the
jugular vein indicating that NTG exerts its migraine- or
cluster headache-inducing effect without involving this
neuropeptide [38].
Studies on external jugular venous blood
in cluster headache
For studies in which CGRP levels were measured in the EJV
during cluster headache attacks, see Table 1. In total 42
cluster headache attacks were investigated. Thirteen of these
attacks were spontaneous attacks [19] and 29 were induced by
sublingual nitroglycerin (NTG) [19, 20]. In the spontaneous
attacks an increase in CGRP (mean 110 ± 7 pmol/l) in the
EJV was found compared to controls (41 ± 6 pmol/l) and
there was a normalization of CGRP levels to 38 ± 6 pmol/l
after either subcutaneous sumatriptan 6 mg or O2 inhalation
[19] (Table 1). In the patients treated with pethidine there was
no similar decrease in CGRP [19]. In the other studies [20, 21]
the baseline values before administration of NTG were
Table 1 Overview of CGRP levels (pmol/l) in external jugular vein during cluster headache [15–17]
Cluster headache attacks
During attacks pmol/l After treatment (after spontaneous
resolution or outside attack)
Thirteen patients with spontaneous cluster headache attacks [19] 110 ± 7 38 ± 6a
Controls 41 ± 6
Twelve NTG induced cluster headache attacks [20] 46 ± 3
Baselineb: 20 ± 2
22 ± 2 (after spontaneous resolution)
Six NTG induced cluster headache attacks [20] 50 ± 4
Baselineb: 18 ± 2
22 ± 2c
NTG induced cluster headache in 11 patients [21] 52 ± 7
Baselineb: 19 ± 2
22 ± 2c
Results are given the mean ± SE
a Treatment with either subcutaneous sumatriptan 6 mg or O2
b Baseline before sublingual nitroglycerin 0.9 mg
c Treatment with subcutaneous sumatriptan 6 mg
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determined. In both studies CGRP was more than doubled
during the cluster headache attacks and spontaneous resolu-
tion of attacks or resolution after sumatriptan normalised the
CGRP levels in EJV (Table 1) [20, 21]. The most extensive
study [21] is illustrated in Fig. 1. It can be seen that vasodi-
lator NTG per se did not increase the CGRP levels. Also at the
beginning of the cluster headache attack there was no increase
but after 1 h there was a doubling of the CGRP levels, and
subcutaneous sumatriptan 6 mg resulted in resolution of
attacks and normalization of CGRP levels [21].
Thus, in contrast to migraine (see below), there is no
doubt that CGRP is increased in EJV in cluster headache.
In the three studies there is both an approximately twofold
increase in CGRP during attacks and a normalization of
CGRP occurred after spontaneous resolution or treatment
with either sumatriptan or O2 [19–21].
Studies on external jugular venous blood in migraine
An overview of studies in which CGRP levels were measured
in the EJV during migraine is given Table 2. In two studies,
(n = 22) [17] and (n = 8) [18], from the Australian and
Swedish group by Goadsby and Edvinsson there were
increased levels of CGRP during migraine attacks (Table 2).
During attacks CGRP decreased in seven out of eight patients
responding to sumatriptan treatment [18] (Fig. 2). In contrast,
in the Danish study (n = 17) with intra-patient comparison
there was not even a tendency for an increase during migraine
attack of migraine without aura (Table 2) [22]. This was the
case where whether CGRP was measured with the same
radioimmunoassay as used previously by Goadsby and Edv-
insson [17, 18] or another sensitive assay [23]. There was an
excellent intrapatient consistency between levels in EJV
blood and cubital blood during migraine attacks with both
assays indicating that no CGRP was released from the extra-
cranial tissue [22].
These different findings in the EJV [17, 18, 22] are very
difficult to reconcile. Are there differences in the patient
populations? In the first two ‘positive’ studies a mixture of
migraine with and without aura was investigated [17, 18],
whereas in the ‘negative’ study only migraine without aura
patients was studied [22]. In the first study the increased blood
levels of CGRP was, however, similar during migraine
with aura (92 pmol/l, n = 10) and migraine without aura
(86 pmol/l, n = 12) [17]. The controls levels were\40 pmol/l.
The controls were 12 healthy females aged between 19 and
25 years [17]. The mean age in the migraine patients was
36 years (range 22–58 years) in the migraine patients [17]
which was roughly similar to the patients in the Danish study:
mean age 39 years, range 26–53 years [22]. The female/male
sex ratios were 16/6 [17] and 17/4 [22], respectively. The
influence of sex and age was studied in one large study with
cubital blood in 223 normal individuals and serum levels of
CGRP (mean 36 pmol/l) were unrelated to sex and age [23].
It has recently been stated [24] that ‘‘CGRP is released
in prolonged, severe attacks of migraine’’ with a reference
to [17]. The duration of the actual studied attacks were,
however, similar in two of the studies [17, 22] with either
‘positive’ or ‘negative’ results, both median 3 h, range
1–7 h [17] and mean 201 min, range 95–305 min [22]
whereas in the third study the median was 11 h and the
Fig. 1 CGRP levels (pmol/l) in external julular vein during nitroglyc-
erin (NTG)-induced cluster headache. Note that NTG per se did not
increase CGRP. At the start of the cluster headache attacks there was no
increase in CGRP. At the maximum of attack CGRP increased twofold.
Sumatriptan caused a normalization of CGRP levels, redrawn from [21]
Table 2 Overview of CGRP
levels (pmol/l) in external
jugular vein during and outside
migraine attacks [13, 14, 18]
Results are given the
mean ± SE
a Treatment with subcutaneous
sumatriptan 6 mg
Migraine attacks
During attacks pmol/l After treatment (after spontaneous
resolution or outside attack)
Ten migraine with aura (MA) [17] 92 ± 11
Twelve migraine without aura (MO) [17] 86 ± 4
Controls \40
Two MA and six MO [18] 60 ± 8 40 ± 8a
Seventeen MO patients [22]
Assay I 17 (range \10–42) 16 (range \10–28) (outside attacks)
Assay II 33 (range 5–57) 31 (range 14–61)
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range was 1 1
2
h to 3 1
2
weeks (sic) [18]. The severity of
headache in these three studies cannot be compared
because in two of the studies with ‘positive’ results there
are no data on headache severity [17, 18]. In the study
with intrapatient comparison, in which all patients ful-
filled the diagnostic criteria for migraine without aura
[39], the headache was severe in seven, moderate in 13
and mild in one patient [22]. The headache was unilateral
in 19 patients [22]. There was no correlation between
CGRP levels and severity and duration of attacks [22]. In
the second ‘positive’ study (n = 8) no controls were used
but CGRP levels before (mean 60 pmol/l) and after sub-
cutaneous sumatriptan (mean 40 pmol/l) (P = 0.016,
Sign test) were measured [18] (Fig. 2). It has been argued
that the decrease in CGRP levels after sumatriptan could
be an effect of the drug per se and not related to the anti-
migraine effect of sumatriptan [22]. The argument was
based on an in vitro study, showing depression of CGRP
in trigeminal cells by sumatriptan [40], but in human
volunteers subcutaneous sumatriptan was without any
effect on CGRP levels in the EJV [41]. The effect of
sumatriptan on CGRP is thus most likely caused by an
anti-migraine effect.
Thus, for migraine there is some uncertainty as to
whether CGRP is increased in the EJV in all migraine
patients. There are two ‘positive’ studies [17, 18], finding
increased CGRP during migraine attacks, whereas the
study with the best methodology, the intra-patient com-
parison, did not find even an indication of an increase in
CGRP [22]. More studies are needed in order to settle the
question of whether CGRP is increased in migraine.
One should not just repeat previous studies but go for
the optimum design. This was used in one of the cluster
headache studies [21]. CGRP was measured before, after
provocation with NTG, at the beginning of attack, at the
maximum of attack and after the attack was resolved [21].
Such a design used in migraine with i.v. NTG provocation
of attacks [42, 43] is somewhat cumbersome, but since
NTG triggers genuine migraine attacks [42, 43] it would
once and for all settle the question of whether CGRP is
increased in EJV during migraine attacks.
Other studies with CGRP in cubital blood and internal
jugular blood
In two of the studies mentioned earlier [17, 22], no increase
in CGRP in the cubital blood during migraine attacks was
observed, whereas Gallai et al. found an increase of CGRP
in 30 young, migraine-with-aura patients and 45 young,
migraine-without-aura patients when studied during (mean
56 ? 7 pmol l) and outside attacks (mean 39 ± 9 pmol l)
[41]. Since there are no indications that younger migraine
patients have a different migraine pathophysiology than
adults, the ‘positive’ study [44] remains unexplained for it
is difficult to understand how an increase in CGRP in EJV
(blood flow 160 ml/min) could be picked up in the systemic
circulation (minute volume 5,000 ml/min). Similarly, no
increase of CCGRP could be detected (detection limit
20 pmol/l) [45] in the cubital vein during trigeminal thermo-
coagulation [46].
In nitroglycerin-induced migraine attacks there was a
minor but significant increase (6 pmol/l) of CGRP level in
cubital blood in one study [47] and there was a correlation
between plasma levels of CGRP and severity of migraine
[47]. In another study using nitroglycerin provocation
migraine patients, that responded to intranasal sumatriptan
20 mg had a minor (17–15 pmol/l, n = 6) decrease in
CGRP level in cubital blood after sumatriptan, whereas this
was not the case for non-responders (24–24 pmol/l,
n = 13) [48].
In one study CGRP levels in a cubital vein was
unchanged after 10, 20 and 60 min nitroglycerin infusion
[49].
In one small Italian study (n = 5) of CGRP in the
internal jugular venous blood was found increased with a
maximum after 1 h during repeated measurement up to 6
and 2 h after the migraine without aura attacks which were
spontaneous and untreated [50]. In contrast, this was not
the case in a small Danish study (n = 4) of CGRP in
internal jugular venous blood studied during migraine aura
[51]. The arterial CGRP levels were in all cases (n = 8)
greater than the control value of \40 pmol/l [51].
The specificity of the CGRP for primary headaches was
demonstrated in one study of cervicogenic headache in
which samples were taken from EJV and anticubital vein
[52]. No difference was found between CGRP levels










during attack after suma
pmol/l
Fig. 2 Effect of subcutaneous sumatriptan 6 mg on CGRP levels
(pmol/l) in external jugular vein during migraine attacks (n = 8).
Seven of eight patients responded to sumatriptan and in all these cases
a decrease in CGRP levels was observed. One patient did not respond
and there was no change in CGRP levels in this patient [18]
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Which tissues does the EJV drain?
The bulk of EJV blood flow comes from the extracranial
tissue of head and face. In addition, the middle meningeal
veins go through the foramen spinosum drain into the
pterygoidal plexus [53] and this is a tributary to the EJV.
The blood flow in the meningeal veins is likely to be
comparable to blood flow in middle meningeal artery
(MMA) Blood flow in the MMA in man is unknown.
According to Fig. 940 in Spalteholz [53] the MMA is only
a minor ramification of the external carotid artery. It is
even smaller than the superficial temporal artery. Based on
this indirect estimation blood flow in the middle meningeal
veins contributes only to a small fraction of to blood in
the EJV.
It is generally not known that 22% of the blood flow in
the EJV comes from the cerebral circulation in man [54].
The venous circulation of the brain has numerous, but
small, communication with extracerebral pathways. These
are the emissary veins of the skull and the veins passing
through the foramens of the base of the skull and the orbit
and the veins which communicate with the pterygoid
plexus [54]. Based on the possible increase of CGRP in
internal jugular vein of an increase of 40 pmol/l found in
one study [50], and based on a 22% contribution of cerebral
blood to the EJV blood flow, it can be estimated that the
contribution of cerebral blood can theoretically increase
CGRP levels in EJV with 8 pmol/l. This calculation pre-
sumes that the analyses of CGRP are comparable, which is
not the case (see Table 1). Anyway, this theoretical cal-
culation indicates that only a smaller part of CGRP in EJV
during cluster headache and possibly migraine is likely to
come from the cerebral circulation (see Table 1).
In addition, the lack of increase in CGRP in EJV blood
after CSD in cats [27] would indicate that the increased
CGRP levels in the EJV during migraine with aura [17], in
which CSD is the most likely the primary putative event
[55, 56], is not derived from the brain. The CGRP in blood
in EJV is thus most likely derived from part of the vas-
culature without BBB.
Other relevant studies in man
In this section, I will review some studies on arterial and
blood flow changes relevant to a possible increase in CGRP
in the EJV during migraine attacks and a certain increase
during cluster headache attacks.
During 25 migraine attacks the temporal artery, as
measured with ultrasound, during and outside attacks, on
the symptomatic was not constricted whereas this was the
case for the temporal artery on the non-symptomatic side
[57]. In addition, the radial arteries were constricted during
migraine attacks [57]. This indicates a general vasocon-
strictory effect during the migraine attack [57]. Similarly,
the temporal artery on the symptomatic side in cluster
headache attacks (n = 9) was not constricted whereas this
was the case on the non-symptomatic [58]. This indicates
that there is an extracranial ‘‘vasodilatory drive’’ present on
the symptomatic side during migraine and cluster headache
[57, 58].
Only patients (n = 6) with facial flushing during tri-
geminal thermocoagulation showed an increase in CGRP
in the EJV [31] whereas the patients (n = 3) without
flushing showed no change. This supports the hypothesis
that a ‘‘nervous vasodilatory drive’’ is necessary for release
of CGRP from the extracranial vasculare bed. Thermo-
graphic studies have shown that facial flushing after
thermocoagulation of Gasserian ganglion can be shown to
be associated with increased skin temperature [59]. In
cluster headache heat loss was increased from the affected
orbital region. O2 treatment, which was effective in 22 of
25 patients, caused the asymmetry of heat loss to disappear
[60]. Also in half-sided migraine attacks the ipsilateral-side
had greater heat loss than the contralateral asymptomatic
side [61].
That CGRP can be involved in flushing was also shown
in a double-blind study in which intravenous administered
human a-CGRP 2 lg/kg per min caused flushing in the
head and upper part of the body [62] whereas this was not
the case after placebo. The flushing can be inhibited by the
CGRP antagonist BIBN4096BS (olcegepant) [62] which
also inhibited headache and extracranial vasodilatation
[62].
Conclusion
Im migraine there are two ‘postive’ studies [17, 18] dem-
onstrating increased CGRP levels in EJV during attacks
whereas a negative study, using intra-patient comparison,
found no change in CGRP in EJV [22]. For migraine there
is thus some uncertainty as to whether CGRP in EJV is
increased in all migraine patients; and more research,
preferably with the intra-patient design with repeated
measurements after provocation with NTG [21] (see
above), is recommended.
For cluster headache there are three studies, one in
spontaneous attacks [19] and two in nitroglycerin induced
attacks [20, 21], which showed an increase in CGRP levels
in EJV with normalisation after sumatriptan, O2 inhalation
or spontaneous resolution.
The bulk of the blood in the EJV comes from the
extracranial tissue and the face; only onefifth comes from
the cerebral circulation [54]. Thus, changes in CGRP found
in the EJV most likely reflect what is going on in this
J Headache Pain (2009) 10:137–143 141
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extracranial tissue that it drains. It has been shown with
ultrasound that the temporal artery on the symptomatic
headache is not constricted during migraine or cluster
headache attacks whereas the artery is constricted on the
contralateral side [57, 58]. These findings indicate that
there is a ‘vasodilator drive’ on the symptomatic side
counteracting a vasonstriction and at the same time
releasing CGRP from nerves in this vascular bed.
How this fits into the migraine inducing effect of CGRP
[1] and the efficacy of CGRP-antagonists in migraine [2–4]
remains unclear. The issue whether increased CGRP in
EJV, if present, is more than a ‘marker for the trigemino-
vascular system remains to be investigated.
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